We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 31, 2023

Racial Disparities in Treatment and Outcomes Among Patients With TP53‐Mutated AML



Additional Info

Disclosure statements are available on the authors' profiles:

Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia
Cancer 2022 Dec 21;[EPub Ahead of Print], T Badar, MR Litzow, RM Shallis, A Patel, AN Saliba, M Burkart, JP Bewersdorf, M Stahl, GS De Camargo Correia, GS Guru Murthy, Y Abaza, A Duvall, D Bradshaw, V Kota, S Dinner, AD Goldberg, N Palmisiano, A Al Kali, E Atallah

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading